» Articles » PMID: 40052359

A Comparative Study of 141 Glial Fibrillary Acidic Protein Immunoglobulin G Positive Cases

Abstract

Background: Glial fibrillary acidic protein-immunoglobulin G (GFAP-IgG) positivity is associated with autoimmune GFAP astrocytopathy (GFAP-A), but also with other autoimmune encephalitides and viral infections. We attempted to elucidate the characteristics of GFAP-A in relation to other GFAP-IgG-positive encephalitides and constructed a differential diagnosis model.

Methods: 141 GFAP-IgG-positive cases were identified, including 52 astrocytopathy (GFAP-A group), 48 autoimmune encephalitis (AE-G), and 41 viral encephalitis (VE-G). Multivariate logistic regression was employed to create a diagnostic model, with validation using an external cohort.

Result: Compared to the AE-G group, the GFAP-A patients showed more onset age ≥ 50 years, headache, fever, consciousness disturbance, MRI radial vascular enhancement, cerebrospinal fluid (CSF) antibody titer grade ≥ 4, and CSF proteins ≥ 700 mg/L, but less female sex, limb numbness, visual disturbances, and CSF chloride ≤ 120 mmol/L. Among these, CSF antibody titer grade ≥ 4, CSF protein ≥ 700 mg/L, and absence of visual disturbances were independent risk factors for GFAP-A diagnosis. Compared to the VE-G group, the GFAP-A patients showed more course ≥ 14 days, onset age ≥ 50 years, limb weakness, serum potassium ≤ 3.9 mmol/L, CSF antibody titer grade ≥ 4, CSF leukocytes ≤ 46*10, MRI radial vascular enhancement, MRI involvement of brainstem, and MRI involvement of spinal cord, but less headache, fever, nausea, and vomiting. Among these, serum potassium ≤ 3.9 mmol/L, MRI spinal cord involvement, and absence of nausea and vomiting were independent risk factors for GFAP-A diagnosis.

Conclusions: Based on critical clinical indicators identified, we constructed a differential diagnosis model for GFAP-A.

References
1.
Brandt A, Oberwahrenbrock T, Mikolajczak J, Zimmermann H, Pruss H, Paul F . Visual dysfunction, but not retinal thinning, following anti-NMDA receptor encephalitis. Neurol Neuroimmunol Neuroinflamm. 2016; 3(2):e198. PMC: 4747477. DOI: 10.1212/NXI.0000000000000198. View

2.
Jarius S, Pellkofer H, Siebert N, Korporal-Kuhnke M, Hummert M, Ringelstein M . Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation. 2020; 17(1):261. PMC: 7470615. DOI: 10.1186/s12974-020-01824-2. View

3.
Yang X, Xu H, Ding M, Huang Q, Chen B, Yang H . Overlapping Autoimmune Syndromes in Patients With Glial Fibrillary Acidic Protein Antibodies. Front Neurol. 2018; 9:251. PMC: 5932346. DOI: 10.3389/fneur.2018.00251. View

4.
Li X, Wang J, Li L, Yang C, Zhao X, Yang B . Epstein-Barr virus: To be a trigger of autoimmune glial fibrillary acidic protein astrocytopathy?. CNS Neurosci Ther. 2023; 29(12):4139-4146. PMC: 10651959. DOI: 10.1111/cns.14336. View

5.
Dalmau J, Graus F . Diagnostic criteria for autoimmune encephalitis: utility and pitfalls for antibody-negative disease. Lancet Neurol. 2023; 22(6):529-540. DOI: 10.1016/S1474-4422(23)00083-2. View